Psychological — Skills Group for Those at Clinical High-Risk for Psychosis
Citation(s)
Beck AT, Baruch E, Balter JM, Steer RA, Warman DM A new instrument for measuring insight: the Beck Cognitive Insight Scale. Schizophr Res. 2004 Jun 1;68(2-3):319-29. doi: 10.1016/S0920-9964(03)00189-0.
Beck AT, Epstein N, Brown G, Steer RA An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988 Dec;56(6):893-7. doi: 10.1037//0022-006x.56.6.893. No abstract available.
BECK AT, WARD CH, MENDELSON M, MOCK J, ERBAUGH J An inventory for measuring depression. Arch Gen Psychiatry. 1961 Jun;4:561-71. doi: 10.1001/archpsyc.1961.01710120031004. No abstract available.
Benedict, R H. B., Schretlen, D., Groninger, L., & Brandt, J. (1998). The Hopkins verbal learning test-revised: Normative data and analysis of interform and test-retest reliability. Clinical Neuropsychologist, 12, 43-55.
Bernstein, D , & Fink, L. (1998). Childhood Trauma Questionnaire: A retrospective self-report. San Antonio, TX: The Psychological Corporation.
Cane, D B. Olinger, L.J,. Gotlib, I.H., Kuiper, N.A. (1986) Factor structure of the Dysfunctional Attitude Scale in a student population. J Clin Psychol. 42, 307 - 309 .
Cohen S, Kamarck T, Mermelstein R A global measure of perceived stress. J Health Soc Behav. 1983 Dec;24(4):385-96. No abstract available.
Greco LA, Baer RA, Smith GT Assessing mindfulness in children and adolescents: development and validation of the Child and Adolescent Mindfulness Measure (CAMM). Psychol Assess. 2011 Sep;23(3):606-14. doi: 10.1037/a0022819.
Greco LA, Lambert W, Baer RA Psychological inflexibility in childhood and adolescence: development and evaluation of the Avoidance and Fusion Questionnaire for Youth. Psychol Assess. 2008 Jun;20(2):93-102. doi: 10.1037/1040-3590.20.2.93.
Gross JJ, John OP Individual differences in two emotion regulation processes: implications for affect, relationships, and well-being. J Pers Soc Psychol. 2003 Aug;85(2):348-62. doi: 10.1037/0022-3514.85.2.348.
Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004 Jun 1;68(2-3):283-97. doi: 10.1016/j.schres.2003.09.011.
Kenardy JA, Spence SH, Macleod AC Screening for posttraumatic stress disorder in children after accidental injury. Pediatrics. 2006 Sep;118(3):1002-9. doi: 10.1542/peds.2006-0406.
Lecomte, T , Leclerc, C. & Wykes, T. 2003. Quick LL. Group CBT for Psychosis: A Guidebook for Clinicians.
Lee, R M., & Robbins, S. B. (1995). Measuring belongingness: The Social Connectedness and the Social Assurance Scales. Journal of Counseling Psychology, 42, 232-241.
Lehman, A , Kernan, E., & Postrado, L.Toolkit Evaluating Quality of Life for Persons with Severe Mental Illness. https://www.hsri.org/publication/toolkit_evaluating_quality_of_life_for_persons_with_severe_mental_illn
Lehman, A F. (1988). A quality of life interview for the chronically mentally ill. Evaluation and Program Planning, 11, 51-62.
Lenz, A S., James, P., Stewart, C. et al. A Preliminary Validation of the Youth Over- and Under-Control (YOU-C) Screening Measure with a Community Sample. Int J Adv Counselling 43, 489-503 (2021). https://doi.org/10.1007/s10447-021-09439-9
Loewy RL, Pearson R, Vinogradov S, Bearden CE, Cannon TD Psychosis risk screening with the Prodromal Questionnaire--brief version (PQ-B). Schizophr Res. 2011 Jun;129(1):42-6. doi: 10.1016/j.schres.2011.03.029. Epub 2011 Apr 20.
Lynch TR, Hempel RJ, Dunkley C Radically Open-Dialectical Behavior Therapy for Disorders of Over-Control: Signaling Matters. Am J Psychother. 2015;69(2):141-62. doi: 10.1176/appi.psychotherapy.2015.69.2.141.
Lynch, T R. (2018b). Radically Open Dialectical Behavior Therapy: Theory and practice for treating disorders of overcontrol. Reno, NV: Context Press, an imprint of New Harbinger Publications, Inc.
McGlashan, T H., Walsh, B. C., Woods, S. W., Addington, J., Cadenhead, K., Cannon, T., & Walker, E. (2001). Structured interview for psychosis-risk syndromes. New Haven, CT: Yale School of Medicine.
Oei, Tian Po & Green, Angela (2008). The Satisfaction With Therapy and Therapist Scale-Revised (STTS-R) for Group Psychotherapy: Psychometric Properties and Confirmatory Factor Analysis. Professional Psychology Research and Practice. 39. 10.1037/0735-7028.39.4.435.
Pelletier-Baldelli A, Strauss GP, Visser KH, Mittal VA Initial development and preliminary psychometric properties of the Prodromal Inventory of Negative Symptoms (PINS). Schizophr Res. 2017 Nov;189:43-49. doi: 10.1016/j.schres.2017.01.055. Epub 2017 Feb 8.
Ritsher JB, Otilingam PG, Grajales M Internalized stigma of mental illness: psychometric properties of a new measure. Psychiatry Res. 2003 Nov 1;121(1):31-49. doi: 10.1016/j.psychres.2003.08.008.
Woods SW, Lympus C, McGlashan TH, Walsh BC, Cannon TD The Mini-SIPS: development of a brief clinical structured interview guide to diagnosing DSM-5 Attenuated Psychosis Syndrome and training outcomes. BMC Psychiatry. 2022 Dec 13;22(1):784. doi: 10.1186/s12888-022-04406-z.
Testing the Feasibility of a Skills Group for Adolescents and Young Adults at Clinical High-risk for Psychosis
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.